Research programme: antibacterials - Bayer

Drug Profile

Research programme: antibacterials - Bayer

Alternative Names: 6-Aminouracil-DNA polymerase inhibitors research programme - Bayer; Antibacterials research programme - Bayer; DNA polymerase inhibitors research programme - Bayer; Phe-RS inhibitors research programme – Bayer; Phenylalanyl-tRNA synthetase inhibitors research programme – Bayer

Latest Information Update: 24 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer GeneData
  • Class Sulfonamides
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 16 Mar 2005 A preclinical study has been added to the Bacterial Infections pharmacodynamics and antimicrobial activity sections
  • 14 Jul 2003 This programme is still in active development
  • 21 Sep 2001 Preclinical development for Bacterial infections in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top